Fan Cao

Dr. Fan Cao


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
FCFan Cao
Fan Cao
婧陈婧 陈
婧 陈
ZLZheng-Tao Lin
Zheng-Tao Lin
HLHan-Ying Lin
Han-Ying Lin
BLBin Liu
Bin Liu
YZYonghong Zhang
Yonghong Zhang
Phytochemical investigations of Melia azedarach fruits have led to the isolation of a novel tirucallane triterpenoid (1), four new limonoids (2–5), and four known limonoids (6–9). Their structures were clarified by comprehensive spectroscopic and spectrometric analyses. The anti-inflammatory activities of isolated compounds were assessed in vitro. Compound 2 exhibited the most potent anti-inflammatory effect, with an IC50 value of 22.04 μM. Additionally, compound 2 attenuated LPS-induced reactive oxygen species (ROS) production and reduced the levels of inflammatory mediators IL-6 and TNF-α. A mechanistic study revealed that limonoid 2 suppresses the expression of iNOS and JAK2 and is implicated in the modulation of the NF-κB signaling cascade, which reveals its anti-inflammatory actions.

8 April 2024 in Molecules
Verified
Journal Article
Open access
PDF file
XMxinhua ma
xinhua ma
MWMin Wu
Min Wu
ZCZhenwei Chen
Zhenwei Chen
FCFan Cao
Fan Cao
ZHZhong Tian hua
Zhong Tian hua
ZZZhiqiang Zhang
Zhiqiang Zhang
Two new phenylspirodrimanes, stachybotrins K and L (1 and 2), together with eight known analogues (3–10), were isolated from deep-sea-derived Stachybotrys sp. MCCC 3A00409. Their structures were determined by extensive NMR data and mass spectroscopic analysis. Absolute configurations of new compounds were determined through a comparison of their circular dichroism (CD) spectra with other reported compounds. The possible reversal effects of all compounds were assayed in the resistant cancer cell lines. Stachybotrysin B (8) can reverse multidrug resistance (MDR) in ABCB1-overexpression cells (KBv200, Hela/VCR) at the non-cytotoxic concentration. Doxorubicin accumulation assay and molecular-docking analysis reveal that the mechanism of its reversal MDR effect may be related to the increase in the intracellular concentration of substrate anticancer drugs.